特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
927065

世界の嚢胞性線維症治療薬市場:2020年~2028年の予測

Global Cystic Fibrosis Therapeutics Market Forecast 2020-2028

出版日: | 発行: Inkwood Research | ページ情報: 英文 176 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
世界の嚢胞性線維症治療薬市場:2020年~2028年の予測
出版日: 2020年03月02日
発行: Inkwood Research
ページ情報: 英文 176 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の嚢胞性線維症治療薬市場は、2020年から2028年の予測期間中に10.04%の成長率で拡大する見通しです。世界における嚢胞性線維症の発生率の上昇、嚢胞性線維症に対する薬剤の増加、嚢胞性線維症を治療する薬剤の開発に向けた研究開発投資の増加が同市場の成長を後押ししています。嚢胞性線維症の治療とジェネリック医薬品の導入に伴う高いコストは、同市場の成長を妨げていますが、新興国におけるヘルスケア産業の成長は、今後の市場機会を生み出すと期待されています。

当レポートは世界の嚢胞性線維症治療薬市場について調査しており、市場規模、成長および阻害要因、投与経路・薬剤クラス・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査範囲と方法

  • 調査の目的
  • 調査範囲
  • 調査法
  • 前提条件と制限

第2章 エグゼクティブサマリー

  • 市場規模と推計
  • 市場概況

第3章 市場力学

  • 市場の定義
  • 主な成長要因
    • 嚢胞性線維症治療の進歩
    • 嚢胞性線維症の発生率の増加(CF)
    • 新規嚢胞性線維症治療薬の研究開発の増加
  • 主な阻害要因
    • 厳格な規制
    • 新興経済における低い認識

第4章 主要な分析

  • ポーターのファイブフォース分析
  • PESTEL分析
  • 市場機会マトリックス
  • ベンダー情勢
  • 主要な投資の洞察

第5章 市場分析:投与経路別

  • 吸入
  • 経口

第6章 市場分析:薬剤クラス別

  • CFTR変調器薬
  • 気管支拡張剤
  • ムコライト
  • 膵臓酵素サプリメント

第7章 市場分析:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第8章 企業プロファイル

  • ABBOTT LABORATORIES
  • ABBVIE INC
  • AGILENT TECHNOLOGIES INC
  • ALLERGAN PLC
  • F. HOFFMANN-LA ROCHE
  • GILEAD SCIENCES INC
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • MYLAN N.V
  • NOVARTIS AG
  • PERKINELMER
  • PFIZER INC
  • PHARMAXIS LTD
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • VERTEX PHARMACEUTICALS INCORPORATED
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - VETERINARY VACCINE
  • TABLE 2: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL INHALE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL INHALE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL ORAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL ORAL MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL CFTR MODULATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME
  • TABLE 12: GLOBAL CFTR MODULATORS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL BRONCHODILATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME
  • TABLE 15: GLOBAL BRONCHODILATORS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL MUCOLYTIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME
  • TABLE 18: GLOBAL MUCOLYTIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL PANCREATIC ENZYME SUPPLEMENTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL PANCREATIC ENZYME SUPPLEMENTS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 23: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 24: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 25: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 26: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 27: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 28: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 29: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 30: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019
  • FIGURE 6: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019
  • FIGURE 9: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)
  • FIGURE 13: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 14: THE UNITED STATES CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 15: CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 16: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 17: THE UNITED KINGDOM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 18: FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 20: ITALY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: RUSSIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: BELGIUM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: POLAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 26: CHINA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 27: JAPAN CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 28: INDIA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 29: AUSTRALIA & NEW ZEALAND CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 30: SOUTH KOREA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: THAILAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: INDONESIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: VIETNAM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 34: REST OF ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 36: LATIN AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: MIDDLE EAST & AFRICA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
目次
Product Code: 29841

KEY FINDINGS

The global cystic fibrosis therapeutics market is anticipated to grow at a rate of 10.04% during the estimated period of 2020-2028. A rise in incidences of cystic fibrosis across the globe, an increase in medications against cystic fibrosis, and a hike in R&D investments towards the development of drugs to treat cystic fibrosis are boosting the market.

MARKET INSIGHTS

Cystic fibrosis is a disease that is inherited and mainly affects the lungs and other body parts like the kidney, pancreas, and liver. In cystic fibrosis, thick and sticky mucus is produced by the body that may block the lungs and obstruct the pancreas. There is no cure for the fatal disease, but taking proper medication and nutrition to reduce excess mucus produced in the lungs and kidney can help in increasing the patient's lifespan. The disease is most prevalent in newborns, and has led the researchers towards the development of advanced therapeutics, which may increase the life span of the patients. However, the high costs involved in cystic fibrosis treatment and the introduction of generic drugs impede the market growth. At the same time, the growth of the healthcare industry in developing economies is expected to create profitable opportunities in the future.

REGIONAL INSIGHTS

The global cystic fibrosis therapeutics market is geographically analyzed based on markets situated in North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of Europe holds the largest market share in terms of revenue, and continues the trend by the end of the forecast period. This is attributed to the presence of key players investing largely in the development of new technologies. The market region of Europe is predicted to be the fastest-growing market in terms of revenue. The major factor driving the growth is the surge in incidences of cystic fibrosis in the region.

COMPETITIVE INSIGHTS

Abbott Laboratories, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Pharmaxis Ltd, Novartis International AG, etc. are some of the leading companies registering their presence in the global market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
    • 3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
    • 3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. STRINGENT REGULATION
    • 3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. PESTEL ANALYSIS
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY ROUTE OF ADMINISTRATION

  • 5.1. INHALE
  • 5.2. ORAL

6. MARKET BY DRUG CLASS

  • 6.1. CFTR MODULATORS
  • 6.2. BRONCHODILATORS
  • 6.3. MUCOLYTIC
  • 6.4. PANCREATIC ENZYME SUPPLEMENTS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. THE UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. AUSTRALIA & NEW ZEALAND
    • 7.3.5. SOUTH KOREA
    • 7.3.6. THAILAND
    • 7.3.7. INDONESIA
    • 7.3.8. VIETNAM
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
  • 8.2. ABBVIE INC
  • 8.3. AGILENT TECHNOLOGIES INC
  • 8.4. ALLERGAN PLC
  • 8.5. F. HOFFMANN-LA ROCHE
  • 8.6. GILEAD SCIENCES INC
  • 8.7. GLAXOSMITHKLINE PLC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. MYLAN N.V
  • 8.10. NOVARTIS AG
  • 8.11. PERKINELMER
  • 8.12. PFIZER INC
  • 8.13. PHARMAXIS LTD
  • 8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 8.15. VERTEX PHARMACEUTICALS INCORPORATED
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.